ASPI Nasdaq Miscellaneous Chemical Products Financials FY2022βFY2025
ASP Isotopes Inc. had $23.8M of revenue in fiscal 2025, up 475.5% on the year before.
Last close Β· Oct 23, 2026
$1.95
6.9%Hi! I read ASP Isotopes Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+475.5%
Yes. Sales grew 475.5% last year.
Does it make a profit?
β670.2%
No. It lost money last year.
Does profit turn into cash?
β198.9%
No. It spent more cash than it brought in.
How healthy are the accounts?
5 / 9
Mixed. It passes 5 of 9 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days ASP Isotopes Inc. did it, and the next one. Share prices often move a lot on those days.
Next results
November 18, 2026
Wednesday Β· in 24 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Aug 4, 2026 | Q2 '26 | Before the market opens | 8-K β |
| May 20, 2026 | Q1 '26 | After the market closes | 10-Q β |
| Apr 10, 2026 | Q4 '25 | After the market closes | 10-K β |
| Nov 19, 2025 | Q3 '25 | After the market closes | 10-Q β |
| Aug 14, 2025 | Q2 '25 | After the market closes | 10-Q β |
| May 20, 2025 | Q1 '25 | After the market closes | 10-Q β |
| Mar 31, 2025 | Q4 '24 | After the market closes | 10-K β |
| Nov 19, 2024 | Q3 '24 | After the market closes | 10-Q β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· ASP Isotopes Inc. had $23.8M of revenue in fiscal 2025, up 475.5% on the year before. Its operating margin was β251.2%, up 384.8Β pts: of every 100 in sales, about β251 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
KIRA Β· ASP Isotopes Inc. lost $160M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$47.4M in fiscal 2025, β198.9% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
KIRA Β· ASP Isotopes Inc. returned $0.0M to shareholders in fiscal 2025. The diluted share count rose 49.1%.
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
KIRA Β· ASP Isotopes Inc. has $325M more cash than debt.
Cash, debt and the ratios that show how comfortably ASP Isotopes Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
| Fiscal year end | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Cash and short-term investments | $2.4M | $7.9M | $61.9M | $327M |
| Debt incl. finance leases | β | β | $2.4M | $2.1M |
| Debt / equity | β | β | 0.0x | 0.0x |
| Interest coverage | β | β135.4x | β101.8x | β104.2x |
| Current ratio | 1.7x | 1.9x | 9.3x | 12.2x |
| Quick ratio | 1.7x | 1.9x | 9.3x | 12.2x |
| Total assets | $12.5M | $27.5M | $94.3M | $498M |
| Total liabilities | $2.7M | $8.7M | $43.2M | $235M |
| Shareholders' equity | $9.8M | $16.3M | $47.9M | $204M |
| Net debt (β = net cash) | β | β | β$59.5M | β$325M |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
KIRA Β· ASP Isotopes Inc. passes 5 of 9 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Net income is positive | β | β | β | β |
| Cash from operations is positive | β | β | β | β |
| Return on assets rose | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β |
| Debt fell relative to assets | β | β | β | β |
| Current ratio rose | β | β | β | β |
| Share count didn't rise | β | β | β | β |
| Gross margin rose | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β |
| F-score | β / 3 | β / 6 | 5 / 8 | 5 / 9 |
| Accruals ratio | β16.0% | β54.4% | β25.8% | β41.2% |
| Altman Z'' | β0.15 | β3.62 | 1.43 | 3.43 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $0.0M | $0.4M | $4.1M | $23.8M |
| Net interest income | $0.0M | β | β | β |
| Gross profit | $0.0M | $0.1M | $1.6M | $3.4M |
| Research and development | $1.3M | $0.8M | $3.1M | $12.4M |
| Operating income | β$5.1M | β$16.0M | β$26.4M | β$59.9M |
| Interest expense | $0.0M | $0.1M | $0.3M | $0.6M |
| Pretax income | β$4.9M | β$16.3M | β$32.3M | β$160M |
| Income tax | $0.0M | β$0.0M | $0.1M | $0.3M |
| Net income | β$4.9M | β$16.3M | β$32.4M | β$160M |
| Diluted EPS | β | β$0.49 | β$0.63 | β$2.11 |
| Diluted shares | β | 0.03B | 0.06B | 0.08B |
| Cash flow | ||||
| Cash from operations | β$2.9M | β$5.4M | β$16.7M | β$37.8M |
| Capital expenditure | $4.5M | $2.3M | $9.7M | $9.7M |
| Free cash flow | β$7.4M | β$7.7M | β$26.4M | β$47.4M |
| Depreciation and amortization | $0.0M | $0.0M | $0.5M | $1.9M |
| Stock-based compensation | $2.0M | $8.7M | $8.6M | $16.0M |
| Dividends paid | β | $0.0M | $2.8M | $0.0M |
| Dividends and buybacks | β | $0.0M | $2.8M | $0.0M |
| Balance sheet | ||||
| Cash and short-term investments | $2.4M | $7.9M | $61.9M | $327M |
| Total debt | β | β | $2.4M | $2.1M |
| Current assets | $3.3M | $10.5M | $65.7M | $400M |
| Current liabilities | $1.9M | $5.7M | $7.1M | $32.7M |
| Inventory | β | $0.0M | $0.1M | $1.1M |
| Property and equipment, net | $8.2M | $10.7M | $22.4M | $33.3M |
| Goodwill | $0.0M | $3.3M | $3.2M | $5.2M |
| Intangible assets | β | β | β | $0.7M |
| Total assets | $12.5M | $27.5M | $94.3M | $498M |
| Total liabilities | $2.7M | $8.7M | $43.2M | $235M |
| Preferred stock | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | $9.8M | $16.3M | $47.9M | $204M |
| Margins | ||||
| Gross margin | β | 32.1% | 38.6% | 14.3% |
| Operating margin | β | β3,704.8% | β636.0% | β251.2% |
| EBITDA margin | β | β3,696.2% | β624.6% | β243.2% |
| Net margin | β | β3,763.1% | β782.4% | β670.2% |
| FCF margin | β | β1,788.4% | β636.4% | β198.9% |
| Returns | ||||
| Return on capital employed | β48.3% | β73.4% | β30.2% | β12.9% |
| Return on equity | β50.4% | β124.8% | β101.0% | β126.8% |
| Return on assets | β39.6% | β81.4% | β53.2% | β54.0% |
| Return on tangible equity | β50.4% | β125.1% | β72.5% | β80.6% |
| Growth | ||||
| Revenue growth | β | β | 857.0% | 475.5% |
| Share count change | β | β | 68.4% | 49.1% |
| Financial health | ||||
| Debt / equity | β | β | 0.0x | 0.0x |
| Interest coverage | β | β135.4x | β101.8x | β104.2x |
| Current ratio | 1.7x | 1.9x | 9.3x | 12.2x |
| Quick ratio | 1.7x | 1.9x | 9.3x | 12.2x |
| Capital allocation | ||||
| Capex / revenue | β | 538.4% | 233.5% | 40.5% |
| Stock comp / revenue | β | 2,019.4% | 206.6% | 67.2% |
| Quality scores | ||||
| Piotroski F-score | β | β | 5.0 | 5.0 |
| Altman Z'' | β0.1 | β3.6 | 1.4 | 3.4 |
| Accruals ratio | β16.0% | β54.4% | β25.8% | β41.2% |
Source: SEC EDGAR XBRL filings (CIK 0001921865). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
